This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Archived

This page has been archived on the Web.

Health product recall

Teva-Tolterodine (2016-08-04)

Starting date:
August 4, 2016
Posting date:
August 11, 2016
Type of communication:
Drug Recall
Subcategory:
Drugs
Hazard classification:
Type II
Source of recall:
Health Canada
Issue:
Product Safety
Audience:
General Public, Healthcare Professionals, Hospitals
Identification number:
RA-59776

Affected products

  1. Teva-Tolterodine 1mg
  2. Teva-Tolterodine 2mg

Reason

Presence of fungal/mold organisms traced to raw material used in the formulation.

Depth of distribution

Pharmacies and Wholesalers Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland, Nova Scotia, Ontario, Quebec and Saskatchewan

Affected products

A. Teva-Tolterodine 1mg

DIN, NPN, DIN-HIM
DIN 02299593
Dosage form

Tablet

Strength

1mg

Lot or serial number

0T2003

Companies
Recalling Firm
Teva Canada Ltd.
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
Marketing Authorization Holder
Teva Canada Ltd.
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA

B. Teva-Tolterodine 2mg

DIN, NPN, DIN-HIM
DIN 02299607
Dosage form

Tablet

Strength

2mg

Lot or serial number

0T3003

Companies
Recalling Firm
Teva Canada Ltd.
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
Marketing Authorization Holder
Teva Canada Ltd.
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA

Date modified: